Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
Thalidomide Chemical Structure
Thalidomide can directly inhibit angiogenesis induced by bFGF or VEGF in vivo.
Thalidomide was commonly used therapeutically in the late 1950's; however, it was withdrawn from the market when it was discovered to cause birth defects. More recent research has found Thalidomide to affect key biochemical pathways yielding antiangiogenic and immunomodulatory activities. This compound has been shown to: selectively inhibit tumor necrosis factor-alpha (TNF alpha) biosynthesis and basic fibroblast growth factor (bFGF)-induced angiogenesis, induce apoptosis in human monocytes via a cytochrome c-dependent pathway, and to inhibit HIV-1 replication in a monocytoid (U1) line. These new found uses make Thalidomide an extremely valuable research tool.
|M.Wt||258.23||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
DMSO >20 mg/mL
|1 mg||5 mg||10 mg|
|1 mM||3.8725 mL||19.3626 mL||38.7252 mL|
|5 mM||0.7745 mL||3.8725 mL||7.7450 mL|
|10 mM||0.3873 mL||1.9363 mL||3.8725 mL|
|Product Name||Sponsor Only||Condition||Start Date||End Date||Phase||Last Change Date|
|Thalidomide||Millennium Pharmaceuticals Inc||Multiple myeloma||30-JUN-07||31-MAY-13||Phase 3||03-JUL-13|
|Second Military Medical University PLA||Multiple myeloma||30-JUN-10||30-JUN-14||Phase 4||13-SEP-13|
|University of Arkansas||Multiple myeloma||30-NOV-06||30-APR-13||Phase 3||14-NOV-13|
|PETHEMA Foundation||Multiple myeloma||31-JAN-07||30-JUN-10||Phase 4||20-SEP-11|
|University of Cincinnati||Uveitis||31-JAN-04||31-AUG-06||Phase 4||10-SEP-13|
Other Countries & RegionsSee Worldwide Distributors